Abstract:Qualitative and quantitative measurement of urine protein excretion is one of the most common tests performed during pregnancy. For more than 100 years, proteinuria was necessary for the diagnosis of preeclampsia, but recent guidelines recommend that proteinuria is sufficient but not necessary for the diagnosis. Still, in clinical practice, most patients with gestational hypertension will be diagnosed as having preeclampsia based on the presence of proteinuria. Although the reference standard for measuring urinary protein excretion is a 24-hour urine collection, spot urine protein-to-creatinine ratio is a reasonable "rule-out" test for proteinuria. Urine dipstick screening for proteinuria does not provide any clinical benefit and should not be used to diagnose proteinuria. The classic cutoff cited to define proteinuria during pregnancy is a value of >300 mg/24 hours or a urine protein-to-creatinine ratio of at least 0.3. Using this cutoff, the rate of isolated proteinuria in pregnancy may reach 8%, whereas preeclampsia occurs among 3% to 8% of pregnancies. Although this threshold is widely accepted, its origin is not based on evidence on adverse pregnancy outcomes but rather on expert opinion and results of small studies. After reviewing the available data, the most important factor that influences maternal and neonatal outcome is the severity of blood pressures and presence of end organ damage, rather than the excess protein excretion. Because the management of gestational hypertension and preeclampsia without severe features is almost identical in frequency of surveillance and timing of delivery, the separation into 2 disorders is unnecessary. If the management of women with gestational hypertension with a positive assessment of proteinuria will not change, we believe that urine assessment for proteinuria is unnecessary in women who develop new-onset blood pressure at or after 20 weeks' gestation. Furthermore, we do not recommend repeated measurement of proteinuria for women with preeclampsia, the amount of proteinuria does not seem to be related to poor maternal and neonatal outcomes, and monitoring proteinuria may lead to unindicated preterm deliveries and related neonatal complications. Our current diagnosis of preeclampsia in women with chronic kidney disease may be based on a change in protein excretion, a baseline protein excretion evaluation is critical in certain conditions such as chronic hypertension, diabetes, and autoimmune or other renal disorders. The current definition of superimposed preeclampsia possesses a diagnostic dilemma, and it is unclear whether a change in the baseline proteinuria reflects another systemic disease such as preeclampsia or whether women with chronic disease such as chronic hypertension or diabetes will experience a different "normal" pattern of protein excretion during pregnancy. Finally, limited data are available regarding angiogenic and other biomarkers in women with chronic kidney disease as a potential aid in distinguishing the worsening of baseline chronic kidney disease and chronic hypertension from superimposed preeclampsia.

Urine congophilia associated with preeclampsia does not persist 6-months postpartum

Diagnostics of preeclampsia based on Congo red binding to urinary components: Rationales and limitations

The high-resolution mass spectrometry study of the protein composition of amyloid-like urine aggregates associated with preeclampsia

Alterations in Serum Adipocyte Fatty Acid Binding Protein and Retinol Binding Protein-4 in Normal Pregnancy and Preeclampsia.

Serum and Placental Interleukin-18 Are Elevated in Preeclampsia

Urinary protein and coagulation‐fibrinolysis indicators in preeclampsia: Expression and significance

Alteration of Serum Endocan in Normal Pregnancy and Preeclampsia

Correlation between 24-h urine protein, spot urine protein/creatinine ratio, and serum uric acid and their association with fetomaternal outcomes in preeclamptic women

Serum Follistatin-Like-3 Was Elevated in Second Trimester of Pregnant Women Who Subsequently Developed Preeclampsia

Correlation of 24-h Urinary Protein Excretion, Serum Indicators, and Placental Growth Factor in Patients with Preeclampsia and their Adverse Outcome

Determining the relationship between severity of proteinuria and adverse maternal and neonatal outcomes in patients with preeclampsia

The association between protein levels in 24-hour urine samples and maternal and neonatal outcomes of pregnant women with preeclampsia

Changes of serum cardiotropin I and cystatin C in preeclampsia and significance thereof

Urine excretion of C3dg and sC5b-9 coincide with proteinuria and development of preeclampsia in pregnant women with type-1 diabetes

Study on the Relation Between Concentration of Circulating Non-Host Fetal DNA in Pregnant Women and Pre-Eclampsia

Proteinuria during pregnancy: definition, pathophysiology, methodology, and clinical significance

Isobaric tag for relative and absolute quantitation based quantitative proteomics reveals unique urinary protein profiles in patients with preeclampsia

Effective Prediction of Preeclampsia by Measuring Serum Angiotensin II, Urinary Angiotensinogen and Urinary Transforming Growth Factor Β1.

Association of serum copeptin and urinary uromodulin with kidney function, blood pressure and albuminuria at 6 weeks post-partum in pre-eclampsia

A correlation of 8-hour and 12-hour with 24-hour urinary protein among pregnant women with preeclampsia in a teaching hospital in South-Western Nigeria

Characterization of discriminatory urinary proteomic biomarkers for severe preeclampsia using SELDI-TOF mass spectrometry